Quest Magazine

ALS Research: Blocking SOD1

A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four additional U.S. sites.

DMD Research: Drug Company On Board

On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon skipping” compound PRO051 for Duchenne muscular dystrophy (DMD).

The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.

ALS Research: Blocking SOD1

A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four additional U.S. sites.

ALS TDI Webcast

A Webcast is now available of the fourth annual research symposium held as part of the ALS TDI Leadership Summit 2009 on Oct. 5. The symposium was conducted at the MDA-supported ALS Therapy Development Institute in Cambridge, Mass.

ALS TDI Webcast

A Webcast is now available of the fourth annual research symposium held as part of the ALS TDI Leadership Summit 2009 on Oct. 5. The symposium was conducted at the MDA-supported ALS Therapy Development Institute in Cambridge, Mass.

Trial of SOD1 Blocker in Familial ALS to Open Soon

A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four additional U.S. sites.

New ALS TDI Research Symposium Now Online





ALS TDI Laboratory
MDA and the ALS Therapy Development Institute began a jointly funded, $36 million ALS drug development project in 2007.

Major Pharmaceutical Company Commits to Develop Exon Skipping Drug

On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon skipping” compound PRO051 for Duchenne muscular dystrophy (DMD).

The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.

New ALS Care Guidelines Released

The American Academy of Neurology (AAN) released its new guidelines on patient care in amyotrophic lateral sclerosis (ALS) on Oct. 13, 2009. Several MDA-affiliated physicians were involved in their development.

Major Pharmaceutical Company Commits to Develop Exon-Skipping Drug

On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon-skipping” compound PRO051 for Duchenne muscular dystrophy (DMD).

The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.

Pages